Full text is available at the source.
Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents
How Ketamine, Esketamine, and Dextromethorphan Affect Constant NMDA Receptor Activity in Major Depression and What This Means for New Drug Development
AI simplified
Abstract
Up to 50% of adults with major depressive disorder may experience treatment-resistant depression after using two or more antidepressants.
- Elevated tonic currents mediated by NR2C/D subunits in NMDA receptors are implicated in the pathophysiology of treatment-resistant depression.
- Sustained ambient-glutamate signaling occurs in key limbic regions, as documented by in vivo studies.
- Ketamine, esketamine, and dextromethorphan may produce rapid and sustained antidepressant effects through selective dampening of NR2C/D-mediated tonic currents.
- Ketamine and esketamine's affinity for NR2A/B subunits may lead to dissociative effects, which are not observed with dextromethorphan.
- Future drug discovery could focus on subunit-biased ligands and allosteric modulators to enhance antidepressant efficacy and tolerability.
AI simplified